Caredx reports preliminary revenue results for fourth quarter and full year 2022

Brisbane, calif.--( business wire )--caredx, inc. (nasdaq: cdna) – the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported preliminary financial results for the fourth quarter and full year ended december 31, 2022.
CDNA Ratings Summary
CDNA Quant Ranking